A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B

References

• World Health Organization. Global hepatitis report; 2017. www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
   Google Scholar
• Gerlich WH. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol. 2015;204:39–55.
   PubMed Web of Science ®Google Scholar
• Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, Nanji A, Yuen ST, Williams R and Naoumov NV. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology. 2002;122(3):614–24. doi:10.1053/gast.2002.31887.
   PubMed Web of Science ®Google Scholar
• Rehermann B, Lau D, Hoofnagle JH and Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest. 1996;97(7):1655–65. doi:10.1172/JCI118592.
   PubMed Web of Science ®Google Scholar
• Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH and Chisari FV. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68–76. doi:10.1128/JVI.77.1.68-76.2003.
   PubMed Web of Science ®Google Scholar
• Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL and Schluep T. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antiviral Res. 2015;121:47–58. doi:10.1016/j.antiviral.2015.06.008.
   PubMed Web of Science ®Google Scholar
• Sun D, Zhu L, Yao D, Chen L, Fu L and Ouyang L. Recent progress in potential anti-hepatitis B virus agents: structural and pharmacological perspectives. Eur J Med Chem. 2018;147:205–17. doi:10.1016/j.ejmech.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Asselah T, Marcellin P and Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018;38(Suppl 1):7–13. doi:10.1111/liv.13673.
   PubMed Web of Science ®Google Scholar
• Guo JT, Guo H. Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res. 2015;122:91–100. doi:10.1016/j.antiviral.2015.08.005.
   PubMed Web of Science ®Google Scholar
• Rehermann B. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses. Semin Liver Dis. 2007;27(2):152–60. doi:10.1055/s-2007-979468.
   PubMed Web of Science ®Google Scholar
• Rehermann B, Thimme R. Insights from antiviral therapy into immune responses to hepatitis B and C virus infection. Gastroenterology. 2019;156(2):369–83. doi:10.1053/j.gastro.2018.08.061.
   PubMed Web of Science ®Google Scholar
• Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2009;106(21):8623–28. doi:10.1073/pnas.0809818106.
   PubMed Web of Science ®Google Scholar
• Cho H, Kang H, HH L, CW K. Programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis. Int J Mol Sci. 2017;18(7):1517. doi:10.3390/ijms18071517
   Web of Science ®Google Scholar
• Fisicaro P, Barili V, Montanini B, Acerbi G, Ferracin M, Guerrieri F, Salerno D, Boni C, Massari M, Cavallo MC, et al. Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med. 2017;23(3):327–36.
   PubMed Web of Science ®Google Scholar
• Jung MK, Shin EC. Regulatory T cells in hepatitis B and C virus infections. Immune Netw. 2016;16(6):330–36. doi:10.4110/in.2016.16.6.330.
   PubMed Web of Science ®Google Scholar
• Wang FS, Xing LH, Liu MX, Zhu CL, Liu HG, Wang HF and Lei ZY. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J Gastroenterol. 2001;7(4):537–41. doi:10.3748/wjg.v7.i4.537.
   PubMed Web of Science ®Google Scholar
• Gehring AJ, Protzer U. Targeting innate and adaptive immune responses to cure chronic HBV infection. Gastroenterology. 2019;156(2):325–37. doi:10.1053/j.gastro.2018.10.032.
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Le Bert N. Immunotherapy for chronic hepatitis B virus infection. Gut Liver. 2018;12:497–507.
   PubMed Web of Science ®Google Scholar
• Block TM, Rawat S and Brosgart CL. Chronic hepatitis B: a wave of new therapies on the horizon. Antiviral Res. 2015;121:69–81. doi:10.1016/j.antiviral.2015.06.014.
   PubMed Web of Science ®Google Scholar
• Dawood A, Abdul Basit S, Jayaraj M and Gish RG. Drugs in development for hepatitis B. Drugs. 2017;77(12):1263–80. doi:10.1007/s40265-017-0769-2.
   PubMed Web of Science ®Google Scholar
• Boni C, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D, Penna A, Missale G, Ferrari C, Fisicaro P. HBV immune-therapy: from molecular mechanisms to clinical applications. Int J Mol Sci. 2019;20:11. doi:10.3390/ijms20112754.
   Google Scholar
• Kosinska AD, Bauer T and Protzer U. Therapeutic vaccination for chronic hepatitis B. Curr Opin Virol. 2017;23:75–81. doi:10.1016/j.coviro.2017.03.011.
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Gehring AJ. Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog. 2013;9(12):e1003784. doi:10.1371/journal.ppat.1003784.
   PubMed Web of Science ®Google Scholar
• Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM and Lok AS. Present and future therapies of hepatitis B: from discovery to cure. Hepatology. 2015;62(6):1893–908. doi:10.1002/hep.28025.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Inaba K, Turley S, Pierre P and Mellman I. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol. 1999;60(7):562–67. doi:10.1016/S0198-8859(99)00030-0.
   PubMed Web of Science ®Google Scholar
• Martinez-Pomares L. The mannose receptor. J Leukoc Biol. 2012;92(6):1177–86. doi:10.1189/jlb.0512231.
   PubMed Web of Science ®Google Scholar
• Guilliams M, Bruhns P, Saeys Y, Hammad H and Lambrecht BN. The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94–108. doi:10.1038/nri3582.
   PubMed Web of Science ®Google Scholar
• Caminschi I, Lahoud MH and Shortman K. Enhancing immune responses by targeting antigen to DC. Eur J Immunol. 2009;39(4):931–38. doi:10.1002/eji.200839035.
   PubMed Web of Science ®Google Scholar
• Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, Garbi N, Kaisho T, Germain RN and Kastenmuller W. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell. 2015;162(6):1322–37. doi:10.1016/j.cell.2015.08.004.
   PubMed Web of Science ®Google Scholar
• Kastenmuller W, Kastenmuller K, Kurts C and Seder RA. Dendritic cell-targeted vaccines–hope or hype? Nat Rev Immunol. 2014;14(10):705–11. doi:10.1038/nri3727.
   PubMed Web of Science ®Google Scholar
• Altmann F, Staudacher E, Wilson IB and Marz L. Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J. 1999;16(2):109–23. doi:10.1023/A:1026488408951.
   PubMed Web of Science ®Google Scholar
• Shi X, Jarvis DL. Protein N-glycosylation in the baculovirus-insect cell system. Curr Drug Targets. 2007;8(10):1116–25. doi:10.2174/138945007782151360.
   PubMed Web of Science ®Google Scholar
• Urbanowicz RA, Wang R, Schiel JE, Keck ZY, Kerzic MC, Lau P, Rangarajan S, Garagusi KJ, Tan L, Guest JD, et al. Antigenicity and immunogenicity of differentially glycosylated hepatitis C virus E2 envelope proteins expressed in mammalian and insect cells. J Virol. 2019;93:7. doi:10.1128/JVI.01403-18.
   Web of Science ®Google Scholar
• Al-Barwani F, Young SL, Baird MA, Larsen DS and Ward VK. Mannosylation of virus-like particles enhances internalization by antigen presenting cells. PLoS One. 2014;9(8):e104523. doi:10.1371/journal.pone.0104523.
   PubMed Web of Science ®Google Scholar
• Lohr HF, Krug S, Herr W, Weyer S, Schlaak J, Wolfel T, Gerken G, Meyer Zum Buschenfelde KH. Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Liver. 1998;18(6):405–13. doi:10.1111/j.1600-0676.1998.tb00825.x.
   PubMedGoogle Scholar
• Nystrom J, Chen A, Frelin L, Ahlen G, Koh S, Brass A, Peterson DL, Fons M, Milich DR, Hultgren C, et al. Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes. J Infect Dis. 2010;201(12):1867–79. doi:10.1086/651178.
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Chisari FV, Penna A, Guilhot S, Galati L, Missale G, Fowler P, Schlicht HJ, Vitiello A, Chesnut RC, et al. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol. 1993;67(4):2376–80.
   PubMed Web of Science ®Google Scholar
• Chen X, Li M, Le X, Ma W and Zhou B. Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection. Vaccine. 2004;22(3–4):439–46. doi:10.1016/j.vaccine.2003.07.014.
   PubMed Web of Science ®Google Scholar
• Gruener NH, Gerlach TJ, Ulsenheimer A, Diepolder HM, Wierenga E, Zachoval R, Heeg M, Pape GR and Jung MC. Characterization of sequence variations in immunodominant regions of the HBV-nucleocapsid protein as a prerequisite for the development of an epitope-based vaccine. Vaccine. 2007;25(26):4960–66. doi:10.1016/j.vaccine.2006.12.009.
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A, Moriarty A and Thornton GB. Immune response to hepatitis B virus core antigen (HBcAg): localization of T cell recognition sites within HBcAg/HBeAg. J Immunol. 1987;139:1223–31.
   PubMed Web of Science ®Google Scholar
• Yang BF, Zhao HL, Xue C, Xiong XH, Zhang W, Yao XQ and Liu ZM. Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response. Vaccine. 2007;25(22):4478–86. doi:10.1016/j.vaccine.2007.03.020.
   PubMed Web of Science ®Google Scholar
• Cai X, Zheng W, Pan S, Zhang S, Xie Y, Guo H, Wang G, Li Z and Luo M. A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice. Antiviral Res. 2018;149:48–57. doi:10.1016/j.antiviral.2017.11.007.
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A, Chisari FV, Kent SB and Thorton GB. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol. 1986;137:315–22.
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Stanson J, Shurin MR and Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol. 2004;173(3):1526–34. doi:10.4049/jimmunol.173.3.1526.
   PubMed Web of Science ®Google Scholar
• Pickl WF, Majdic O, Kohl P, Stockl J, Riedl E, Scheinecker C, Bello-Fernandez C and Knapp W. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol. 1996;157:3850–59.
   PubMed Web of Science ®Google Scholar
• Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci U S A. 1996;93(6):2588–92. doi:10.1073/pnas.93.6.2588.
   PubMed Web of Science ®Google Scholar
• Davis MM, Altman JD and Newell EW. Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat Rev Immunol. 2011;11(8):551–58. doi:10.1038/nri3020.
   PubMed Web of Science ®Google Scholar
• Atienza JM, Yu N, Kirstein SL, Xi B, Wang X, Xu X and Abassi YA. Dynamic and label-free cell-based assays using the real-time cell electronic sensing system. Assay Drug Dev Technol. 2006;4(5):597–607. doi:10.1089/adt.2006.4.597.
   PubMed Web of Science ®Google Scholar
• Xing JZ, Zhu L, Gabos S and Xie L. Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol In Vitro. 2006;20(6):995–1004. doi:10.1016/j.tiv.2005.12.008.
   PubMed Web of Science ®Google Scholar
• Xing JZ, Zhu L, Jackson JA, Gabos S, Sun XJ, Wang XB and Xu X. Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol. 2005;18(2):154–61. doi:10.1021/tx049721 s.
   PubMed Web of Science ®Google Scholar
• Boyd JM, Huang L, Xie L, Moe B, Gabos S and Li XF. A cell-microelectronic sensing technique for profiling cytotoxicity of chemicals. Anal Chim Acta. 2008;615(1):80–87. doi:10.1016/j.aca.2008.03.047.
   PubMed Web of Science ®Google Scholar
• Xia Y, Xing JZ and Krukoff TL. Neuroprotective effects of R,R-tetrahydrochrysene against glutamate-induced cell death through anti-excitotoxic and antioxidant actions involving estrogen receptor-dependent and -independent pathways. Neuroscience. 2009;162(2):292–306. doi:10.1016/j.neuroscience.2009.04.068.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang X, Xu X and Abassi YA. Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods. 2006;309(1–2):25–33. doi:10.1016/j.jim.2005.10.018.
   PubMed Web of Science ®Google Scholar
• Embgenbroich M, Burgdorf S. Current concepts of antigen cross-presentation. Front Immunol. 2018;9:1643. doi:10.3389/fimmu.2018.01643.
   PubMed Web of Science ®Google Scholar
• Guagliardi LE, Koppelman B, Blum JS, Marks MS, Cresswell P and Brodsky FM. Co-localization of molecules involved in antigen processing and presentation in an early endocytic compartment. Nature. 1990;343(6254):133–39. doi:10.1038/343133a0.
   PubMed Web of Science ®Google Scholar
• Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hosel M, Michler T, Wisskirchen K, Cheng X, Zhang K, et al. Interferon-gamma and tumor necrosis factor-alpha produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016;150(1):194–205. doi:10.1053/j.gastro.2015.09.026.
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R and Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284(5415):825–29. doi:10.1126/science.284.5415.825.
   PubMed Web of Science ®Google Scholar
• Yang PL, Althage A, Chung J, Maier H, Wieland S, Isogawa M and Chisari FV. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010;107(2):798–802. doi:10.1073/pnas.0913498107.
   PubMed Web of Science ®Google Scholar
• George R, Ma A, Motyka B, Shi YE, Liu Q, Griebel P. A dendritic cell-targeted chimeric hepatitis B virus immunotherapeutic vaccine induces both cellular and humoral immune responses in vivo manuscript submitted to human vaccines and immunotherapeutics. Hum Vaccin Immunother. 2019 Nov 5. doi:10.1080/21645515.2019.168908.
   Google Scholar
• Ashley CW, Baecher-Allan C. Cutting edge: responder T cells regulate human DR+ effector regulatory T cell activity via granzyme B. J Immunol. 2009;183(8):4843–47. doi:10.4049/jimmunol.0900845.
   PubMed Web of Science ®Google Scholar
• Cerignoli F, Abassi YA, Lamarche BJ, Guenther G, Santa Ana D, Guimet D, Zhang W, Zhang J, Xi B. In vitro immunotherapy potency assays using real-time cell analysis. PLoS One. 2018;13(3):e0193498. doi:10.1371/journal.pone.0193498.
   PubMed Web of Science ®Google Scholar
• Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019;4(7):545–58. doi:10.1016/S2468-1253(19)30119-0.
   PubMed Web of Science ®Google Scholar
• Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH, Khan MS and Rahman S. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int. 2013;7(4):981–89. doi:10.1007/s12072-013-9486-4.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhu K, Bai W, Jia B, Hu H, Zhou D, Zhang X, Zhang X, Xie Y, Bourgine MM, et al. Adenoviral delivery of recombinant hepatitis B virus expressing foreign antigenic epitopes for immunotherapy of persistent viral infection. J Virol. 2014;88(5):3004–15. doi:10.1128/JVI.02756-13.
   PubMed Web of Science ®Google Scholar
• Cova L. Present and future DNA vaccines for chronic hepatitis B treatment. Expert Opin Biol Ther. 2017;17(2):185–95. doi:10.1080/14712598.2017.1265940.
   PubMed Web of Science ®Google Scholar
• Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, Hegge JO, Klein JJ, Wakefield DH, Oropeza CE, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013;21(5):973–85. doi:10.1038/mt.2013.31.
   PubMed Web of Science ®Google Scholar
• Du K, Liu J, Broering R, Zhang X, Yang D, Dittmer U and Lu M. Recent advances in the discovery and development of TLR ligands as novel therapeutics for chronic HBV and HIV infections. Expert Opin Drug Discov. 2018;13(7):661–70. doi:10.1080/17460441.2018.1473372.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang TY, Yuan Q and Xia NS. Antibody-mediated immunotherapy against chronic hepatitis B virus infection. Hum Vaccin Immunother. 2017;13(8):1768–73. doi:10.1080/21645515.2017.1319021.
   PubMed Web of Science ®Google Scholar
• Yang L, Lu M. Small molecule inhibitors of hepatitis B virus nucleocapsid assembly: a new approach to treat chronic HBV infection. Curr Med Chem. 2018;25(7):802–13. doi:10.2174/0929867324666170704121800.
   PubMed Web of Science ®Google Scholar
• Akbar SM, Horiike N, Onji M and Hino O. Dendritic cells and chronic hepatitis virus carriers. Intervirology. 2001;44(4):199–208. doi:10.1159/000050047.
   PubMed Web of Science ®Google Scholar
• Vigano M, Grossi G, Loglio A and Lampertico P. Treatment of hepatitis B: is there still a role for interferon? Liver Int. 2018;38(Suppl 1):79–83. doi:10.1111/liv.13635.
   PubMedGoogle Scholar
• Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123–29. doi:10.1016/S0140-6736(05)17701-0.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351(12):1206–17. doi:10.1056/NEJMoa040431.
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–95. doi:10.1056/NEJMoa043470.
   PubMed Web of Science ®Google Scholar
• Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, Nosotti L, Mari T, De Santis A, Ponti ML, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther. 2009;14(8):1165–74. doi:10.3851/IMP1466.
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Chittmittraprap S, Poovorawan K, Limothai U, Khlaiphuengsin A, Chuaypen N, Wisedopas N and Poovorawan Y. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: role of host and viral factors associated with treatment response. J Viral Hepat. 2016;23(6):427–38. doi:10.1111/jvh.12467.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang WL, Lim SG, Tabak F, Mehta R, et al. Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology. 2016;150(1):134–144.e10. doi:10.1053/j.gastro.2015.09.043.
   PubMed Web of Science ®Google Scholar
• Ahn SH, Marcellin P, Ma X, Caruntu FA, Tak WY, Elkhashab M, Chuang WL, Tabak F, Mehta R, Petersen J, et al. Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon Alfa-2a: week 120 analysis. Dig Dis Sci. 2018;63(12):3487–97. doi:10.1007/s10620-018-5251-9.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Brunetto MR, Craxi A, Gaeta GB, Rizzetto M, Rozzi A and Colombo M. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D. J Viral Hepat. 2019;26(1):118–25. doi:10.1111/jvh.12999.
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol. 2005;6(4):353–60. doi:10.1038/ni1181.
   PubMed Web of Science ®Google Scholar
• Suvas S, Kumaraguru U, Pack CD, Lee S and Rouse BT. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med. 2003;198(6):889–901. doi:10.1084/jem.20030171.
   PubMed Web of Science ®Google Scholar
• Franzese O, Kennedy PT, Gehring AJ, Gotto J, Williams R, Maini MK and Bertoletti A. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol. 2005;79(6):3322–28. doi:10.1128/JVI.79.6.3322-3328.2005.
   PubMed Web of Science ®Google Scholar
• Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG and Janssen HL. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology. 2005;41(4):771–78. doi:10.1002/hep.20649.
   PubMed Web of Science ®Google Scholar
• Peng G, Li S, Wu W, Sun Z, Chen Y and Chen Z. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology. 2008;123(1):57–65. doi:10.1111/j.1365-2567.2007.02691.x.
   PubMed Web of Science ®Google Scholar
• Kosinska AD, Zhang E, Lu M, Roggendorf M. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat. 2010;2010:817580.
   PubMedGoogle Scholar
• Maini MK, Pallett LJ. Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. Lancet Gastroenterol Hepatol. 2018;3(3):192–202. doi:10.1016/S2468-1253(18)30007-4.
   PubMed Web of Science ®Google Scholar
• Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol. 2010;52(4):616–19. doi:10.1016/j.jhep.2009.12.017.
   PubMed Web of Science ®Google Scholar
• Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol. 2015;12(3):258–63. doi:10.1038/cmi.2014.79.
   PubMed Web of Science ®Google Scholar
• Protzer U, Knolle P. “To be or not to be”: immune tolerance in chronic hepatitis B. Gastroenterology. 2016;151(5):805–06. doi:10.1053/j.gastro.2016.09.038.
   PubMed Web of Science ®Google Scholar
• Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001;33(6):1527–32. doi:10.1053/jhep.2001.25084.
   PubMed Web of Science ®Google Scholar
• Li J, Bao M, Ge J, Ren S, Zhou T, Qi F, Pu X and Dou J. Research progress of therapeutic vaccines for treating chronic hepatitis B. Hum Vaccin Immunother. 2017;13(5):986–97. doi:10.1080/21645515.2016.1276125.
   PubMed Web of Science ®Google Scholar
• TH K, CB K, Guo Z, Mann D, Lu Y, Coeshott C, AJ G, Bertoletti A, ZZ H, Delaney W, et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One. 2014;9(7):e101904. doi:10.1371/journal.pone.0101904.
   PubMed Web of Science ®Google Scholar
• Lok AS, Pan CQ, Han SH, Trinh HN, Fessel WJ, Rodell T, Massetto B, Lin L, Gaggar A, Subramanian GM, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016;65(3):509–16. doi:10.1016/j.jhep.2016.05.016.
   PubMed Web of Science ®Google Scholar
• Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol. 2013;59(3):450–56. doi:10.1016/j.jhep.2013.05.003.
   PubMed Web of Science ®Google Scholar
• Zoulim F, Fournier C, Habersetzer F, Sprinzl M, Pol S, Coffin CS, Leroy V, Ma M, Wedemeyer H, Lohse AW, et al. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother. 2019. pp.1–12. doi:10.1080/21645515.2019.1651141.
   PubMed Web of Science ®Google Scholar
• Zaiss AK, Machado HB and Herschman HR. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem. 2009;108(4):778–90. doi:10.1002/jcb.22328.
   PubMed Web of Science ®Google Scholar
• Fausther-Bovendo H, Kobinger GP. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important? Hum Vaccin Immunother. 2014;10(10):2875–84. doi:10.4161/hv.29594.
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881–93. doi:10.1016/S0140-6736(08)61591-3.
   PubMed Web of Science ®Google Scholar
• Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med. 2013;19(4):465–72. doi:10.1038/nm.3105.
   PubMed Web of Science ®Google Scholar
• Shortman K, Lahoud MH and Caminschi I. Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med. 2009;41(2):61–66. doi:10.3858/emm.2009.41.2.008.
   PubMed Web of Science ®Google Scholar
• Wang XY, Wang B and Wen YM. From therapeutic antibodies to immune complex vaccines. NPJ Vaccines. 2019;4:2. doi:10.1038/s41541-018-0095-z.
   PubMed Web of Science ®Google Scholar
• Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, Clifton GT, Sukhumalchandra P, Ma Q, Reddy SM, et al. Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res. 2017;77(19):5374–83. doi:10.1158/0008-5472.CAN-16-2774.
   PubMed Web of Science ®Google Scholar
• Wen YM, Mu L and Shi Y. Immunoregulatory functions of immune complexes in vaccine and therapy. EMBO Mol Med. 2016;8(10):1120–33. doi:10.15252/emmm.201606593.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R and Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10(5):317–27. doi:10.1038/nri2744.
   PubMed Web of Science ®Google Scholar
• Salazar G, Zhang N, Fu TM and An Z. Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines. 2017;2:19. doi:10.1038/s41541-017-0019-3.
   PubMed Web of Science ®Google Scholar
• Delamarre L, Pack M, Chang H, Mellman I and Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. 2005;307(5715):1630–34. doi:10.1126/science.1108003.
   PubMed Web of Science ®Google Scholar
• Manca F, Fenoglio D, Li Pira G, Kunkl A and Celada F. Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J Exp Med. 1991;173(1):37–48. doi:10.1084/jem.173.1.37.
   PubMed Web of Science ®Google Scholar
• Noujaim AA, Schultes BC, Baum RP, Madiyalakan R. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13–evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm. 2001;16(3):187–203. doi:10.1089/10849780152389384.
   PubMed Web of Science ®Google Scholar